International generic name Haloperidol
Drug form and composition Solution for injection. One ampoule of 1 ml contains 5 mg Haloperidol.
Indications Psychomotor excitation in acute psychosis of different genesis (reactive psychosis, schizoaffective psychosis) acute neurosis with anxiety and tenseness; vomiting, resistant to other medicines.
Dosage and administration In acute psychosis - 2-5 mg intramuscularly. The same dose may be repeated in 1-hour or in 4-8-hours, in order to control clinical manifestations. Maximal daily dose in severe cases is 100 mg. In prompt treatment of the acute psychosis Haloperidol can be applied slowly intravenously (5 mg per minute) in dose 20-50 mg. If necessary the same dose can be repeated in 30 minutes. Alternatively the dose can be diluted in 30-50 ml saline and applied as an intravenous infusion within 30 minutes. Duration of the treatment and dosage should be individualized, depending on the disease, its severity, and patient toleration.
Contraindications Parkinson’s disease; hypersensitivity to the preparation; epilepsy; hyperthyroidism; glaucoma; coronary artery disease; severe hepatal and renal diseases; pregnancy and lactation.
Special warnings and precautions It long-term treatment hepatic and renal function, blood count and blood coagulation indices should be monitored. The preparation should be combined with care with analgesic and hypnotic medicines, as it considerably increases their effects. During the treatment with Haloperidol alcohol consumption should be avoided.
Drug interactions Haloperidol potentiates the effect of the medicines influencing CNS; diminishes the convulsion threshold and indirectly reduces effectiveness of the anti-epileptic medicines; potentiates effects of atihypertensive medicines, lithium preparations, and alcohol; reduces the effect of anticoagulant drugs. Cholinolytic agents reduce extrapyramidal symptoms caused by Haloperidol.
Adverse reactions Following symptoms may develop: dyskinesia; rigidity; somnolence; depression; ataxia; convulsions; mouth drying; constipation; and rash. In long-term treatment hyperprolactinemia and body weight increasing were described. Occasionally conduction disturbances and tachycardia may appear.
Pharmacological mechanisms Haloperidol, being a butyrophenone derivative, is a neuroleptic. Butyrpherones possess a powerful dopaminolytic and more weak adrenolytic action. Haloperidol possesses prominent antipsychotic and anxiolytic effects. It blocks mainly post- and presynaptic D2-dopamine receptors in CNS. Its effect appears rapidly. For this reason the preparation is considered an appropriate medicine for prompt treatment of the psychomotor excitation in different psychotic conditions. Haloperidol is a powerful antiemetic.
Supplied 10 or 100 ampoules of 1 ml (5 mg).
Expiry 3 years. |